How to Help Your Patients Save Money on Nevirapine: A Provider's Guide to Savings Programs

For patients living with HIV, medication cost is not an abstract concern — it directly impacts adherence. When patients ration doses, delay refills, or abandon prescriptions because of cost, viral suppression suffers and resistance can emerge. As a provider, understanding the savings landscape for nevirapine empowers you to proactively address financial barriers at the point of prescribing. This guide covers all major programs and strategies available in 2026.

Understanding Nevirapine's Cost Landscape

Nevirapine is available only as a generic (brand-name Viramune and Viramune XR are discontinued). At retail without assistance, the 200 mg IR tablet can cost $1,300 or more for a 60-tablet supply at some pharmacies. However, with discount programs, the same prescription costs as little as $19–$35. The 400 mg ER tablet runs $62–$90 with discount cards.

The good news: for most patients, nevirapine should be highly affordable or essentially free through one of several programs. The challenge is that patients often don't know these programs exist, and enrollment can require provider support.

Program 1: AIDS Drug Assistance Program (ADAP)

ADAP — part of the Ryan White HIV/AIDS Program (RWHAP) — is the most important safety net for uninsured and underinsured patients. ADAP provides HIV antiretroviral medications at no cost or significantly reduced cost. Eligibility is determined by income (typically up to 300–400% of the federal poverty level, varying by state), HIV diagnosis, and state residency.

Clinical actions for providers:

Screen all HIV patients for ADAP eligibility at intake and annually

Engage your social worker or case manager for ADAP applications — documentation of HIV diagnosis from your clinic is typically required

Know your state's ADAP formulary — most state ADAPs cover nevirapine, and ADAP-affiliated pharmacies maintain dedicated stock

Even insured patients may benefit from ADAP supplemental programs that cover copays not covered by insurance

Program 2: 340B Drug Pricing Program

If your practice is a qualifying 340B entity (Ryan White grantees, FQHCs, STD/TB clinics, and others), patients can access medications — including nevirapine — at dramatically reduced cost through 340B contract pharmacies. 340B pricing for nevirapine can be as low as a few dollars per prescription.

For providers practicing at eligible entities, ensure your 340B program includes nevirapine and that patients are routed to 340B contract pharmacies when applicable. Your 340B administrator can help identify which pharmacies in your area participate in your program's contract pharmacy arrangements.

Program 3: Medicaid

Medicaid covers HIV antiretrovirals including nevirapine for qualifying low-income patients, typically with copays of $0–$3. In states with expanded Medicaid under the ACA, eligibility extends to individuals with incomes up to 138% of the federal poverty level. Providers should proactively screen patients for Medicaid eligibility and assist with enrollment when appropriate.

39,049+ patients found their medications in stock

39K+

Find Nevirapine In Stock Today →

Program 4: Medicare Part D for Older Patients

For Medicare patients, nevirapine generic is typically covered on Tier 1 or Tier 2 of Part D plans, with low copays. As of 2026, the Medicare Part D out-of-pocket cap is $2,100 annually. For patients whose nevirapine is on Tier 3 or above, a formulary exception or appeal may be warranted. Consider using Medicare's Low Income Subsidy (Extra Help) for patients who qualify — this can reduce or eliminate Part D copays.

Program 5: Prescription Discount Cards (GoodRx, SingleCare)

For patients who don't qualify for or are waiting on ADAP enrollment, prescription discount cards are a reliable bridge. GoodRx offers nevirapine 200 mg for as low as $27 per prescription; SingleCare can bring it to $19. These programs require no enrollment, no income verification, and are available immediately. Provide patients with GoodRx or SingleCare information as a starting point while longer-term assistance is arranged.

Note: There are no active manufacturer savings programs for nevirapine — Boehringer Ingelheim discontinued the brand Viramune and all associated patient assistance programs. Discount cards are the best short-term solution outside of ADAP.

Skip the calls, skip the stress.

Find Nevirapine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Cost-Driven Regimen Considerations

A key clinical consideration: if a patient is on nevirapine primarily for cost reasons, it's worth periodically re-evaluating whether that rationale still holds. ADAP, Medicaid, and manufacturer savings programs for newer agents (like dolutegravir-based regimens) may now make switching affordable — potentially to a regimen with better tolerability, simpler dosing, and fewer drug interactions. The Ryan White program supports switch discussions, and manufacturers of newer ARTs often have robust patient assistance programs that can make the newer, preferred agents equally or more affordable.

Building a Cost-Sensitive Prescribing Workflow

Best practices for providers:

Screen for cost barriers at every visit — brief questions about medication access can surface adherence problems early

Integrate ADAP enrollment into your clinic's new patient workflow

Partner with a specialty pharmacy that has expertise in HIV assistance program navigation

Prescribe 90-day supplies whenever insurance allows — this reduces per-refill burden and cost

Know your 340B status — if eligible, use it actively to reduce medication cost for every qualifying patient

medfinder supports providers and their patients in locating nevirapine when access barriers arise. Learn more at medfinder.com/providers.